Cover Image
市場調查報告書

皮肌炎:開發中產品分析

Dermatomyositis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 361637
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
皮肌炎:開發中產品分析 Dermatomyositis - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 65 Pages
簡介

本報告提供皮肌炎治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

皮肌炎概要

治療藥的開發

  • 開發中產品的概要

皮肌炎:企業開發中的治療藥

皮肌炎:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

皮肌炎:企業開發中的產品

皮肌炎的治療藥的開發企業

  • F. Hoffmann-La Roche Ltd.
  • Hope Pharmaceuticals, Inc.
  • Idera Pharmaceuticals, Inc.
  • MedImmune, LLC
  • Neovacs SA
  • Novartis AG

皮肌炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

皮肌炎:最近的開發平台趨勢

皮肌炎:暫停中的計劃

皮肌炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8765IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H2 2016, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 1 and 2 respectively.Dermatomyositis.

Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dermatomyositis Overview
  • Therapeutics Development
    • Pipeline Products for Dermatomyositis - Overview
  • Dermatomyositis - Therapeutics under Development by Companies
  • Dermatomyositis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Dermatomyositis - Products under Development by Companies
  • Dermatomyositis - Companies Involved in Therapeutics Development
    • F. Hoffmann-La Roche Ltd
    • Hope Pharmaceuticals Inc
    • Idera Pharmaceuticals Inc
    • MedImmune LLC
    • Neovacs SA
    • Novartis AG
  • Dermatomyositis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • IMO-8400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JBT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-7734 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • siponimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium thiosulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dermatomyositis - Dormant Projects
  • Dermatomyositis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 28, 2016: Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
      • Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis
      • Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
      • Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015
      • Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis
      • Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis
      • Jun 05, 2015: Corbus Pharmaceuticals Expands Clinical Development of Resunab With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis
      • May 13, 2015: Neovacs granted 1.8 million euros in research tax credit
      • Aug 08, 2014: Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis
      • Mar 13, 2014: Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dermatomyositis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Dermatomyositis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Dermatomyositis - Pipeline by Hope Pharmaceuticals Inc, H2 2016
  • Dermatomyositis - Pipeline by Idera Pharmaceuticals Inc, H2 2016
  • Dermatomyositis - Pipeline by MedImmune LLC, H2 2016
  • Dermatomyositis - Pipeline by Neovacs SA, H2 2016
  • Dermatomyositis - Pipeline by Novartis AG, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dermatomyositis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Dermatomyositis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top